Navigation Links
Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
Date:10/14/2008

Former Director of the Office of National Drug Control Policy to Moderate

First Educational Webinar: When Good Medicines Become Bad Drugs

FRAZER, Pa., Oct. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that it is embarking on a national educational program designed to promote greater awareness among patients, caregivers and the public about the importance of appropriate and responsible use of prescription opioid medications. The initiative, When Good Medicines Become Bad Drugs(SM), will include a series of free educational programs on timely topics. The first webcast, moderated by General Barry R. McCaffrey, former Director of the Office of National Drug Control Policy, will take place on Tuesday, October 21, 2008, from 3:00 p.m. - 4:00 p.m. Eastern, and will focus on safeguarding medications in the home.

"This program is consistent with Cephalon's commitment to ensure that prescription medications are used safely by the appropriate patients," said Dr. Lesley Russell, Executive Vice President and Chief Medical Officer at Cephalon. "Currently, 71 percent of people who abuse prescription pain medicines received them from a friend or family member, not through a doctor's prescription. The aim of this program is to heighten patient and public awareness of, and responsibility for, safeguarding the use of these important medications."

About When Good Medicines Become Bad Drugs Webcast

This free webcast will provide practical tips about what patients, caregivers and the public can do to safeguard medications and help prevent abuse and diversion of prescription opioids. The webcast will take place on October 21, 2008, from 3:00 p.m. - 4:00 p.m. Eastern. Participants can register at http://video.webcasts.com/events/vxmd001/28151/.

Panelists will include:

Moderator: General Barry R. McCaffrey, former Director of the Office of National Drug Control Policy

Jeff Gudin, M.D., Co-Director of the Pain Management Center at Englewood Hospital and Medical Center in New Jersey

Steve Passik, Ph.D., Associate Attending Psychologist at Memorial Sloan-Kettering Cancer Center in New York

Jennifer Bolen, J.D., a patient living with chronic pain and founder of The Legal Side of Pain, a Tennessee-based organization that provides legal guidance regarding use of pain medications

Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [CII], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 10, 2016  IsoRay, Inc. (NYSE MKT: ISR), ... and medical radioisotope applications for the treatment of prostate, ... announced its financial results for the second quarter and ... 2015. --> --> ... of fiscal 2016, which ended December 31, 2015, a ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated ... of two long-standing principal investigators (PI) to the roles of Chief Medical Officer, ... , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare ... training and support program, Sonalinkā„¢ remote monitoring. The inaugural launch of this new ... February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert at SonaCare ...
(Date:2/10/2016)... ... February 10, 2016 , ... Global Stem Cells Group, ... Singapore-based Global Stem Cells Network (GSCN) and its affiliate Global Medical Training ... latest adipose and bone marrow therapies. , Through the new collaboration, Global ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016   Parabon NanoLabs ... the U.S. Army Research Office and the Defense ... and sensitivity of the company,s Snapshot Kinship ... Mission and, more generally, defense-related DNA forensics.  Although ... capabilities (predicting appearance and ancestry from DNA evidence), ...
(Date:1/28/2016)... 2016 Synaptics (NASDAQ: SYNA ), a leading developer ... quarter ended December 31, 2015. --> ... 2016 increased 2 percent compared to the comparable quarter last year ... 2016 was $35.0 million, or $0.93 per diluted share. ... the first quarter of fiscal 2016 grew 9 percent over the ...
(Date:1/22/2016)... DUBLIN , Jan. 22, 2016 /PRNewswire/ ... announced the addition of the "Global ... report to their offering. --> ... of the "Global Biometrics Market in ... offering. --> Research and ...
Breaking Biology News(10 mins):